Analyst Sees Promise in Pfizer Inc. Lung Cancer Drug, Bets on Approval
A potential treatment for advanced lung cancer from Pfizer Inc. has about an 80 percent chance of receiving Food and Drug Administration approval this year, according to a Credit Suisse analyst. The world's largest drugmaker presented research earlier this month on crizotinib that shows the treatment appears to double survival over standard drugs against tumors with a certain genetic mutation. The FDA gave the drug a "Fast Track designation" last December, and the New York drugmaker was able to start submitting batches of data in January, instead of waiting until all studies are completed.